Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Gili Kenet,1,2 Thomas Moulton,3 Brian M Wicklund,4 Sanjay P Ahuja,5 Miguel Escobar,6 Johnny Mahlangu7 1National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel; 2The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel; 3Bayer, Whippany, NJ, USA; 4Children’...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kenet G, Moulton T, Wicklund BM, Ahuja SP, Escobar M, Mahlangu J
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Dove Medical Press 2023-06-01
Saila:	Journal of Blood Medicine
Gaiak:	fviii hemophilia a prophylaxis recombinant proteins octocog alfa
Sarrera elektronikoa:	https://www.dovepress.com/switching-from-sucrose-formulated-rfviii-to-octocog-alfa-bay-81-8973-p-peer-reviewed-fulltext-article-JBM
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!